Klotho is a novel biomarker for good survival in resected large cell neuroendocrine carcinoma of the lung

Lung Cancer

Volumn 72, Issue 3, 2011, Pages 355-359

  Usuda, Jitsuo ^a   Ichinose, Shuji ^a   Ishizumi, Taichirou ^a   Ohtani, Keishi ^a   Inoue, Tatsuya ^a   Saji, Hisashi ^a   Kakihana, Masahiro ^a   Kajiwara, Naohiro ^a   Uchida, Osamu ^a   Nomura, Masaharu ^a   Tsutsui, Hidemitsu ^a   Ohira, Tatsuo ^a   Ikeda, Norihiko ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Biomarker; Klotho; LCNEC; Lung cancer

Indexed keywords

KLOTHO PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG CARCINOMA; LYMPH NODE METASTASIS; LYMPH VESSEL; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; FEMALE; GLUCURONIDASE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79955463824     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.10.008     Document Type: Article

References (31)

1. Travis W.D., Linnoila R.I., Tsokos M.G., Hitchcock C.L., Cutler G.B., Nieman L., et al. Neuroendicrine tumors of the lung with proposed criteria for large-cell neuroendocrine cacinomas. Am J Surg Pathol 1991, 15:529-553.
2. Travis W.D., Corrin B., Shimosato Y. Histological typing of lung and pleural tumors. World Health Organization International Hisotological Classification of Tumors 1999, Springer Verlag, Berlin. 3rd ed.
3. Desler C.M., Ritter J.H., Patterson G.A., Ross E., Bailey M.S., Wick M.R., et al. Clinical-pathologic analysis of 40 patients with large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg 1997, 63:180-185.
4. Cooper W.A., Thourani V.H., Gal A.A., Lee R.B., Mansour K.A., Miller J.I. The surgical spectrum of pulmonary neuroendocrine neoplasms. Chest 2001, 119:14-18.
5. Iyoda A., Hiroshima K., Toyozaki T., Haga Y., Baba M., Fujisawa T., et al. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer 2001, 91:1992-2000.
6. Takei H., Asamura H., Maeshima A., Suzuku K., Kondo H., Niki T., et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 2002, 124:285-292.
7. Asamura H., Kameya T., Matsuno Y., Noguchi M., Tada H., Ishikawa Y., et al. Neuroendocrine neoplasm of the lung: a prognostic spectrum. J Clin Oncol 2006, 24:70-76.
8. Saji H., Tsuboi M., Matsubayashi J., Miyajima K., Shimada Y., Imai K., et al. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Anticancer Drugs 2010, 21:89-93.
9. Paci M., Cavazza A., Annessi V., Putrino I., Ferrari G., De Franco S., et al. Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study. Ann Thorac Surg 2004, 77:1163-1167.
10. Okubo C., Minami Y., Tanaka R., Uchihara T., Anami Y., Furuya S., et al. Analysis of differentially expressed genes in neuroendocrine carcinimas of the lung. J Thorac Oncol 2006, 1:780-786.
11. Freidin B., McShane L.M., Korn E.L. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 2010, 102:152-160.
12. Bartucci M., Morelli C., Mauro L., Ando S., Surmacz E. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res 2001, 61:6747-6754.
13. Wolf I., Sadetzki S., Gluck I., Oberman B., Ben-David M., Papa M.Z., et al. Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. Eur J Cancer 2006, 42:1077-1082.
14. Yee D. Targeting insulin-like growth factor pathways. Br J Cancer 2006, 94:465-468.
15. Zhang H., Fagan D.H., Zeng X., Freeman K.T., Sachdev D., Yee D. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene 2010, 29:2517-2527.
16. Dziadziuszko R., Camidge R., Hirsch F.R. The insulin-like growth factor pathway in lung cancer. J Thorac Oncol 2008, 3:815-818.
17. London S.J., Yuan J.M., Travlos G.S., Gao Y.T., Wilson R.E., Ross R.K., et al. Insulin-like growth factor 1, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China. J Natl Cancer Inst 2002, 94:749-754.
18. Chang Y.S., Wang L., Liu D., Mao L., Hong W.K., Khuri F.R., et al. Correlation between insulin-like growth factor-binding protein 3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 2002, 8:3669-3675.
19. Cohen B.D., Baker D.A., Soderstrom C., Tkalcevic G., Rossi A.M., Miller P.E., et al. Combination therapy enhances the inhibition of tumor growth with fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751, 871. Clin Cancer Res 2005, 11:2063-2073.
20. Ji Q.S., Mulvihill M.J., Rosenfeld-Franklin M., Cooke A., Feng L., Mak G., et al. A novel, potent, and selective insulin-like growth factor-1 receptor kinase inhibitor blocks insulin-like growth factor-1 receptor signaling in vitro and inhibits insulin-like growth factor-1 dependent tumor growth in vivo. Mol Cancer Ther 2007, 6:2158-2167.
21. Kuro-o M., Matsumura Y., Aizawa H., Kawaguchi H., Suga T., Utsugi T., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390:45-51.
22. Matsumura Y., Aizawa H., Shiraki-Iida T., Nagai R., Kuro-o M., Nabeshima Y. Identification of the human klotho gene and its two transcripts encoding membrane and secreted Klotho protein. Biochem Biophys Res Commun 1998, 242:626-630.
23. Kurosu H., Yamamoto M., Clark J.D., Pastor J.V., Nandi A., Gurnari P., et al. Suppression of aging in mice by the hormone Klotho. Science 2005, 309:1829-1833.
24. Wolf I., Levanon-Cohen S., Bose S., Ligumsky H., Sredni B., Kanety H., et al. Klotho: a tumor suppressor and modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene 2008, 27:7094-7105.
25. Wolf I., Laitman Y., Rubinek T., Abramovitz L., Novikov I., Beeri R., et al. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin. Oncogene 2010, 29:26-33.
26. Dhillon T., Mauri F.A., Bellezza G., Cagini L., Barbareschi M., North B.V., et al. Overexpression of the mammalian target rapamycin; a novel biomarker for poor survival in resected early stage non small cell lung cancer. J Thorac Oncol 2010, 5:314-319.
27. Lee Y.J., Kim H.T., Han J.Y., Yun T., Lee G.K., Kim H.Y., et al. First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status. J Thorac Oncol 2010, 5:361-368.
28. Nakao M., Yoshida J., Ishii G., Kawase A., Maeda R., Aokage K., et al. Prognostic impact of node involvement pattern in pulmonary pN1 squamous cell carcinoma patients. J Thorac Oncol 2010, 5:504-509.
29. Ignatius S.H., Ziogas A., Zell J.A. Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung. J Thorac Oncol 2010, 5:420-427.
30. Yamazaki S., Sekine I., Matsuno Y., Takei H., Yamamoto N., Kunitoh H., et al. Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer 2005, 49:217-223.
31. Iyoda A., Hiroshima K., Moriya Y., Takiguchi Y., Sekine Y., Shibuya K., et al. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg 2006, 82:1802-1807.